US approves two gene therapies for sickle cell disease

The U.S. Food and Drug Administration (FDA) on Friday approved two gene therapies for sickle cell disease, including one that is the first treatment in the United States based on the Nobel Prize-winning CRISPR gene editing technology. Casgevy, developed by partners Vertex Pharmaceuticals and CRISPR Therapeutics, and bluebird bio's Lyfgenia were approved for people aged 12 years and older.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/DoXxQUg
via